Tevimbra contains Tislelizumab, a monoclonal antibody that is indicated for the treatment of unresectable or metastatic small-cell lung cancer and gastric adenocarcinoma in adult patients. It can be given as a first line in combination with other chemotherapeutic agents, and also to patients who have previously received chemotherapy.